

Claims:

*Sub B1*  
a 1. Substantially purified form of the polypeptide that comprising the amino-acid sequence shown in SEQ ID NO. ~~1 or 5~~ <sup>4a8</sup>  
5 homologue thereof, fragment thereof or homologue of the fragment.

a 2. A polypeptide according to claim 1 that comprising the amino-acid sequence shown in SEQ ID NO. ~~1 or 5~~ <sup>4a8</sup>

*Sub B2*  
a 3. A cDNA encoding the polypeptide according to claim 1.

a 10 4. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO. ~~2 or 6~~ <sup>1a5</sup> or a fragment cDNA selectively hybridized to the cDNA.

a 5. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO. ~~2 or 6~~ <sup>2a7</sup> or a fragment cDNA selectively hybridized to the cDNA.

15 6. A replication or expression vector carrying the cDNA according to claim 3 to 5.

*Sub B3*  
a 7. A host cell transformed with the replication or expression vector according to claim 6.

20 8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or 2.

9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.

25 10. A pharmaceutical composition containing the

polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.

Add B4